JP2017514847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514847A5 JP2017514847A5 JP2016565676A JP2016565676A JP2017514847A5 JP 2017514847 A5 JP2017514847 A5 JP 2017514847A5 JP 2016565676 A JP2016565676 A JP 2016565676A JP 2016565676 A JP2016565676 A JP 2016565676A JP 2017514847 A5 JP2017514847 A5 JP 2017514847A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- substitution
- sequence represented
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020032081A JP7304629B2 (ja) | 2014-05-06 | 2020-02-27 | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167265.9 | 2014-05-06 | ||
| EP14167265 | 2014-05-06 | ||
| PCT/EP2015/059861 WO2015169804A1 (en) | 2014-05-06 | 2015-05-05 | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020032081A Division JP7304629B2 (ja) | 2014-05-06 | 2020-02-27 | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514847A JP2017514847A (ja) | 2017-06-08 |
| JP2017514847A5 true JP2017514847A5 (enExample) | 2018-06-14 |
Family
ID=50679896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565676A Pending JP2017514847A (ja) | 2014-05-06 | 2015-05-05 | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
| JP2020032081A Active JP7304629B2 (ja) | 2014-05-06 | 2020-02-27 | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020032081A Active JP7304629B2 (ja) | 2014-05-06 | 2020-02-27 | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9757439B2 (enExample) |
| EP (1) | EP3140320B1 (enExample) |
| JP (2) | JP2017514847A (enExample) |
| KR (1) | KR20170002563A (enExample) |
| CN (1) | CN106414493A (enExample) |
| AU (1) | AU2015257774B2 (enExample) |
| BR (1) | BR112016025764A2 (enExample) |
| CA (1) | CA2947963A1 (enExample) |
| CL (1) | CL2016002794A1 (enExample) |
| DK (1) | DK3140320T3 (enExample) |
| ES (1) | ES2716923T3 (enExample) |
| IL (1) | IL248671B (enExample) |
| MX (1) | MX2016014414A (enExample) |
| RU (1) | RU2700929C2 (enExample) |
| SG (2) | SG11201608712PA (enExample) |
| WO (1) | WO2015169804A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| RU2765874C2 (ru) | 2016-10-26 | 2022-02-04 | МОДЕРНАТиЭкс, ИНК. | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
| EP3576780A1 (en) * | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| CN110709094A (zh) | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| CN109550044B (zh) * | 2018-10-19 | 2022-05-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| CA3141084A1 (en) * | 2019-06-12 | 2020-12-17 | Vikram JUNEJA | Neoantigen compositions and uses thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| JP2023535981A (ja) * | 2020-07-29 | 2023-08-22 | スクイーズ バイオテクノロジーズ カンパニー | 有核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法 |
| CN116322752A (zh) * | 2020-07-29 | 2023-06-23 | Sqz生物技术公司 | 使用无核细胞刺激对突变体ras的免疫应答的方法 |
| JP2023550515A (ja) * | 2020-11-24 | 2023-12-01 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体 |
| EP4423256A2 (en) * | 2021-10-28 | 2024-09-04 | Genentech, Inc. | Systems and methods to identify mhc-associated antigens for therapeutic intervention |
| EP4522192A2 (en) * | 2022-05-12 | 2025-03-19 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| WO2025103205A1 (en) * | 2023-11-15 | 2025-05-22 | Ck Life Sciences Development Limited | Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
-
2015
- 2015-05-05 CN CN201580023165.3A patent/CN106414493A/zh active Pending
- 2015-05-05 DK DK15720986.7T patent/DK3140320T3/en active
- 2015-05-05 SG SG11201608712PA patent/SG11201608712PA/en unknown
- 2015-05-05 US US15/308,917 patent/US9757439B2/en not_active Expired - Fee Related
- 2015-05-05 KR KR1020167034070A patent/KR20170002563A/ko not_active Withdrawn
- 2015-05-05 EP EP15720986.7A patent/EP3140320B1/en not_active Revoked
- 2015-05-05 JP JP2016565676A patent/JP2017514847A/ja active Pending
- 2015-05-05 MX MX2016014414A patent/MX2016014414A/es unknown
- 2015-05-05 AU AU2015257774A patent/AU2015257774B2/en not_active Ceased
- 2015-05-05 SG SG10201809701TA patent/SG10201809701TA/en unknown
- 2015-05-05 CA CA2947963A patent/CA2947963A1/en not_active Abandoned
- 2015-05-05 BR BR112016025764-2A patent/BR112016025764A2/pt not_active IP Right Cessation
- 2015-05-05 WO PCT/EP2015/059861 patent/WO2015169804A1/en not_active Ceased
- 2015-05-05 RU RU2016147527A patent/RU2700929C2/ru active
- 2015-05-05 ES ES15720986T patent/ES2716923T3/es active Active
-
2016
- 2016-11-01 IL IL248671A patent/IL248671B/en unknown
- 2016-11-04 CL CL2016002794A patent/CL2016002794A1/es unknown
-
2020
- 2020-02-27 JP JP2020032081A patent/JP7304629B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514847A5 (enExample) | ||
| Tariq et al. | Biliary tract cancers: current knowledge, clinical candidates and future challenges | |
| RU2016147527A (ru) | Пептидная вакцина, включающая пептид ras, содержащий мутации, и химиотерапевтический агент | |
| Gomez‐Martin et al. | Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation | |
| Mitry et al. | Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)–a phase II non-randomised trial | |
| TWI660739B (zh) | 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法 | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| Thuss-Patience et al. | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) | |
| JP2017502081A5 (enExample) | ||
| RU2016127327A (ru) | Смесь пептидов | |
| ES2907489T3 (es) | Métodos para el tratamiento del cáncer | |
| Nakamichi et al. | A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors | |
| BR122023020985A2 (pt) | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton | |
| JP2019532051A5 (enExample) | ||
| JP2017523207A (ja) | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 | |
| Voortman et al. | A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors | |
| Wang et al. | Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer | |
| Jeremić et al. | Radiotherapy Alone vs. Radiochemotherapy in Patients With Favorable Prognosis of Clinical Stage IIIA Non–Small-Cell Lung Cancer | |
| Tiseo et al. | Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? | |
| JP2021500409A5 (enExample) | ||
| Tian et al. | Effect of neoadjuvant chemotherapy treatment on prognosis of patients with advanced gastric cancer: a retrospective study | |
| Wen et al. | Phase II trial of concurrent chemoradiotherapy with S‑1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma | |
| Baykara et al. | Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers | |
| Teets et al. | Avelumab: A novel anti-PD-L1 agent in the treatment of merkel cell carcinoma and urothelial cell carcinoma | |
| Tan et al. | Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis |